Hargreaves R J, Hill R G, Iversen L L
Merck, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K.
Acta Neurochir Suppl (Wien). 1994;60:15-9. doi: 10.1007/978-3-7091-9334-1_4.
It has been reported that several uncompetitive NMDA receptor ion channel blocking agents (phencyclidine, ketamine, dizocilpine, dextrorphan) cause transient reversible vacuolation in neurons in the posterior cingulate cortex of rats. Similar effects have also been observed with competitive glutamate antagonists such as CPP, CGS 19755 and CGP 37849. This transient morphological change has been noted to be coincident anatomically with brain regions showing hypermetabolism after administration of uncompetitive NMDA receptor ion channel blockers and competitive glutamate antagonists. These results therefore indicate that the functional consequences of NMDA receptor blockade with competitive glutamate and uncompetitive channel antagonists are ultimately the same. These changes do not appear to be a prelude to irreversible damage except after relatively high doses of the receptor ion channel antagonists but they have given rise to concern over the safety in use of NMDA antagonists as neuroprotective agents. In contrast, vacuolation has not yet been demonstrated with agents acting at the glycine (L-687,414) or polyamine (eliprodil) modulatory sites of the NMDA receptor complex suggesting that agents acting at these sites may have a greater potential therapeutic window.
据报道,几种非竞争性N-甲基-D-天冬氨酸(NMDA)受体离子通道阻滞剂(苯环利定、氯胺酮、地佐环平、右啡烷)可导致大鼠后扣带回皮质神经元出现短暂可逆性空泡化。在竞争性谷氨酸拮抗剂如CPP、CGS 19755和CGP 37849中也观察到了类似的效应。这种短暂的形态学变化在解剖学上与给予非竞争性NMDA受体离子通道阻滞剂和竞争性谷氨酸拮抗剂后显示出高代谢的脑区一致。因此,这些结果表明,用竞争性谷氨酸拮抗剂和非竞争性通道拮抗剂阻断NMDA受体的功能后果最终是相同的。除了在相对高剂量的受体离子通道拮抗剂作用后,这些变化似乎并不是不可逆损伤的前奏,但它们引发了人们对NMDA拮抗剂作为神经保护剂使用安全性的担忧。相比之下,作用于NMDA受体复合物甘氨酸(L-687,414)或多胺(依利罗地)调节位点的药物尚未证明有空泡化现象,这表明作用于这些位点的药物可能具有更大的潜在治疗窗。